Estrogens in human vascular diseases

Annals of the New York Academy of Sciences

Volumn 1089, Issue , 2006, Pages 431-443

  Klouche, Mariam ^a,b  

^a Zentralkrankenhaus   (Germany)

^b Bremer Zentrum fur Laboratoriumsmedizin   (Germany)

Author keywords

Androgen; ER ; Estrogen; IL 6; Smooth muscle; Vascular; VEGF

Indexed keywords

ANDROGEN; BIOCHANIN A; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HORMONE RECEPTOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; RECEPTOR SUBTYPE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VASCULOTROPIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE COURSE; ESTROGEN ACTIVITY; FIBRINOLYSIS; HEART PROTECTION; HUMAN; KAPOSI SARCOMA; LIPID BLOOD LEVEL; NONHUMAN; PROTEIN EXPRESSION; SMOOTH MUSCLE; VASCULAR DISEASE; VASCULARIZATION; VASODILATATION; ANGIOGENESIS; BLOOD VESSEL; CYTOLOGY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; REVIEW; SEX RATIO;

BLOOD VESSELS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, ESTROGEN; SEX RATIO; VASCULAR DISEASES;

EID: 33847785392     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1386.032     Document Type: Conference Paper

References (57)

1. MENDELSOHN, M.E. & R.H. KARAS. 1999. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340: 1801-1811.
2. MENDELSOHN, M.E. 2002. Protective effects of estrogen on the cardiovascular system. Am. J. Cardiol. 89: 12E-17E.
3. MENDELSOHN, M.E. & R.H. KARAS. 2005. Molecular and cellular basis of cardiovascular gender differences. Science 308: 1583-1587.
4. LIU, P.Y., R.C. CHRISTIAN, M. RUAN, et al. 2005. Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery disease. J. Clin. Endocrinol. Metab. 90: 1041-1046.
5. KHALIL, R.A. 2005. Sex hormones as potential modulators of vascular function in hypertension. Hypertension 46: 249-254.
6. VITTINGHOFF, E., M.G. SHLIPAK, P.D. VAROSY, et al. 2003. Heart and Estrogen/Progestin Replacement Study Research Group. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/Progestin Replacement Study. Ann. Intern. Med. 138: 81-89.
7. HERRINGTON, D.M., D.M. REBOUSSIN, K.P. KLEIN, et al. 2000. The Estrogen Replacement and Atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Control Clin. Trials 21: 257-285.
8. GOEDERT, J.J., F. VITALE, C. LAURIA, et al. 2002. Classical Kaposi's Sarcoma Working Group. Risk factors for classical Kaposi's sarcoma. J. Natl. Cancer Inst. 94: 1712-1718.
9. STAMPFER, M.J., G.A. COLDITZ, W.C. WILLETT, et al. 1991. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N. Engl. J. Med. 325: 756-762.
10. FRIEDMAN-KIEN, A.E. & B.R. SALTZMAN. 1990. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. J. Am. Acad. Dermatol 22: 1237-1250.
11. BOSHOFF, C., Y. ENDO, P.D. COLLINS, et al. 1997. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 278: 290-294.
12. ENSOLI, B. & M.C. SIRIANNI. 1998. Kaposi's sarcoma pathogenesis: a link between immunology and tumor biology. Crit. Rev. Oncog. 9: 107-124.
13. CALABRO, M.L., J. SHELDON, A. FAVERO, et al. 1998. Seroprevalence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 in several regions of Italy. J. Hum. Virol 1: 207-213.
14. KREUTER, A., H. RASOKAT, M. KLOUCHE, et al. 2005. Liposomal pegylated doxorubicin versus low-dose recombinant interferon-alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Investigation 23: 653-659.
15. LING, S., P. KOMESAROFF & K. SUDHIR. 2006. Cellular mechanisms underlying the cardiovascular actions of oestrogens. Clin. Sci. (Lond) 111: 107-118.
16. KUIPER, G.G., E. ENMARK, M. PELTO-HUIKKO, et al. 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93: 5925-5930.
17. MOSSELMAN, S., J. POLMAN & R. DIJKEMA. 1996. ERbeta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392: 49-53.
18. KUIPER, G.G., B. CARLSSON, K. GRANDIEN, et al. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863-870.
19. PAECH, K., P. WEBB, G.G. KUIPER, et al. 1997. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510.
20. WADE, C.B., S. ROBINSON, R.A. SHAPIRO & D.M. DORSA. 2001. Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 142: 2336-2342.
21. RUBANYI, G.M., K. KAUSER & A. JOHNS. 2002. Role of estrogen receptors in the vascular system. Vascul. Pharmacol. 38: 81-88.
22. DEROO, B.J. & K.S. KORACH. 2006. Estrogen receptors and human disease. J. Clin. Invest. 116: 561-570.
23. CHRISTIAN, R.C., P.Y. LIU, S. HARRINGTON, et al. 2006. Intimal estrogen receptor (ER)beta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women. J. Clin. Endocrinol. Metab. 91: 2713-2720.
24. BRENNER, R.M. & O.D. SLAYDEN. 2004. Steroid receptors in blood vessels of the rhesus macaque endometrium: a review. Arch. Histol. Cytol. 67: 411-416.
25. HODGES, Y.K., L. TUNG, X.D. YAN, et al. 2000. Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation 101: 1792-1798.
26. CRITCHLEY, H.O., R.M. BRENNER, T.A. HENDERSON, et al. 2001. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J. Clin. Endocrinol Metab. 86: 1370-1378.
27. LIANG, M., E. EKBLAD, J.A. GUSTAFSSON & B.O. NILSSON. 2001. Stimulation of vascular protein synthesis by activation of oestrogen receptor beta. J. Endocrinol 171: 417-423.
28. SCHREPFER, S., T. DEUSE, T. MUNZEL, et al. 2006. The selective estrogen receptor-beta agonist biochanin A shows vasculoprotective effects without uterotrophic activity. Menopause 13: 489-499.
29. KNAAPEN, M.W., P. SOMERS, H. BORTIER, et al. 2005. Smooth muscle cell hypertrophy in varicose veins is associated with expression of estrogen receptor-beta. J. Vasc. Res. 42: 8-12.
30. SHEARMAN, A.M., J.A. COOPER, P.J. KOTWINSKI, et al. 2006. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ. Res. 98: 590-592.
31. KLOUCHE, M., N. BROCKMEYER, C. KNABBE & S. ROSE-JOHN. 2002. Human herpesvirus 8-derived viral IL-6 induces PTX3 expression in Kaposi's sarcoma cells. AIDS 16: F9-F18.
32. MÜLLBERG, J., T. GEIB, T. JOSTOCK, et al. 2000. IL-6 receptor independent stimulation of human gp130 by viral IL-6. J. Immunol. 164: 4672-4677.
33. KLOUCHE, M., G. CARRUBA, L. CASTAGNETTA & S. ROSE-JOHN. 2004. Virokines in the pathogenesis of cancer - focus on human herpesvirus 8. Ann. N.Y. Acad. Sci. 1028: 329-339.
34. MANGELSDORF, D.J., C. THUMMEL, M. BEATO, et al. 1995. The nuclear receptor superfamily: the second decade. Cell 83: 835-839.
35. COWLEY, S.M., S. HOARE, S. MOSSELMAN & M.G. PARKER. 1997. Estrogen receptors alpha and beta form heterodimers on DNA. J. Biol. Chem. 272: 19858-19862.
36. SMITH, C.L. 1998. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod. 58: 627-632.
37. MENDELSOHN, M.E. 2002. Genomic and nongenomic effects of estrogen in the vasculature. Am. J. Cardiol. 90: 3F-6F.
38. COLLINS, P. & C. WEBB. 1999. Estrogen hits the surface. Nat. Med. 5: 1130-1131.
39. CHAMBLISS, K.L., I.S. YUHANNA, R.G. ANDERSON, et al. 2002. ERbeta has nongenomic action in caveolae. Mol. Endocrinol. 16: 938-946.
40. LU, Q., D.C. PALLAS, H.K. SURKS, et al. 2004. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc. Natl. Acad. Sci. USA 101: 17126-17131.
41. REVANKAR, C.M., D.F. CIMINO, L.A. SKLAR, et al. 2005. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307: 1625-1630.
42. ROSIN, C., M. BRUNNER, S. LEHR, et al. 2006. The formation of platelet-leukocyte aggregates varies during the menstrual cycle. Platelets 17: 61-66.
43. BHAKDI S., M. TORZEWSKI, M. KLOUCHE & M. HEMMES. 1999. Complement and atherogenesis: binding of CRP to degraded, non-oxidized LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol. 19: 2348-2354.
44. KLOUCHE, M., S. GOTTSCHLING, V. GERL, et al. 1998. Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler. Thromb. Vasc. Biol. 18: 1376-1385.
45. KLOUCHE, M., G. PERI & C. KNABBE. 2004. Cholesterol-loading induces expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 175: 221-228.
46. MAY, A.E., R. SCHMIDT, BÖ BÜLBÜL, et al. 2005. Plasminogen and matrix metalloproteinase activation by enzymatically modified LDL in monocytes and smooth muscle cells. Thrombosis Haemostasis 93: 710-715.
47. KLOUCHE, M., S. BHAKDI, S. HEMMES & S. ROSE-JOHN. 1999. Novel path to the activation of vascular smooth muscle cells: upregulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J. Immunol. 163: 4583-4589.
48. KLOUCHE, M., S. ROSE-JOHN, W. SCHMIEDT & S. BHAKDI. 2000. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 101: 1799-1805.
49. LING, S., L. ZHOU, H. LI, et al. 2006. Effects of 17beta-estradiol on growth and apoptosis in human vascular endothelial cells: influence of mechanical strain and tumor necrosis factor-alpha. Steroids 71: 799-808.
50. WANG, Y., Z. WANG, L. WANG, et al. 2006. Estrogen down-regulates nicotine-induced adhesion molecule expression via nongenomic signal pathway in endothelial cells. Int. Immunopharmacol. 6: 892-902.
51. PATTEN, R.D. & R.H. KARAS. 2006. Estrogen replacement and cardiomyocyte protection. Trends Cardiovasc. Med. 16: 69-75.
52. ROSENFELD, M.E., K. KAUSER, B. MARTIN-MCNULTY, et al. 2002. Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intraplaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis 164: 251-259.
53. PERROT-APPLANAT, M., M. ANCELIN, H. BUTEAU-LOZANO, et al. 2000. Ovarian steroids in endometrial angiogenesis. Steroids 65: 599-603.
54. BAUSERO, P., M. BEN-MAHDI, J. MAZUCATELLI, et al. 2000. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am. J. Physiol. Heart Circ. Physiol 279: H2033-H2042.
55. CEBE-SUAREZ, S., A. ZEHNDER-FJALLMAN & K. BALLMER-HOFER. 2006. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol. Life Sci. 63: 601-615.
56. FERRARA, N., H.P. GERBER & J. LECOUTER. 2003. The biology of VEGF and its receptors. Nat. Med. 9: 669-676.
57. HERVE, M.A., G. MEDURI, F.G. PETIT, et al. 2006. Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus. J. Endocrinol. 188: 91-99.